Nokea
If an agonist can produce maximal effects and has high efficacy it's called:
- A. Partial agonist
- B. Antagonist
- C. Agonist-antagonist
- D. Full agonist
Correct Answer: D
Rationale: A full agonist achieves maximal receptor activation and effect.
You may also like to solve these questions
A nurse is planning caring for a client who is has a new prescription for Torsemide. The nurse should plan to monitor for which of the following adverse reactions of this medications? (Select one that does not apply.)
- A. Respiratory acidosis
- B. Hypokalemia
- C. Hypotension
- D. Ototoxicity
Correct Answer: A
Rationale: Torsemide can cause hypokalemia , hypotension , ototoxicity , and dysrhythmias , typical loop diuretic effects.
Sitagliptin has been approved for:
- A. Monotherapy in once-daily doses
- B. Combination therapy with metformin
- C. Both 1 and 2
- D. Neither 1 nor 2
Correct Answer: C
Rationale: Sitagliptin is approved for monotherapy and with metformin , offering flexible type 2 diabetes management.
Which antiepileptic drug in therapeutic doses causes least sedation?
- A. Primidone
- B. Clonazepam
- C. Phenytoin
- D. Phenobarbitone
Correct Answer: C
Rationale: Phenytoin causes less sedation compared to others.
What describes the action of a drug on the body?
- A. Pharmacodynamics
- B. Pharmacokinetics
- C. Microbiology
- D. Physiology
Correct Answer: A
Rationale: Pharmacodynamics studies the effects of a drug on the body, including mechanisms of action and therapeutic effects, unlike pharmacokinetics, which focuses on drug movement.
A genetic variation in how the metabolite of the cancer drug irinotecan SN-38 is inactivated by the body may lead to:
- A. Decreased effectiveness of irinotecan in the treatment of cancer
- B. Increased adverse drug reactions, such as neutropenia
- C. Delayed metabolism of the prodrug irinotecan into the active metabolite SN-38
- D. Increased concerns for irinotecan being carcinogenic
Correct Answer: B
Rationale: UGT1A1 mutations slow SN-38 inactivation, raising neutropenia risk , not affecting efficacy or activation .